Sön 14 aug / År 40 / Nr 3 2022

Providing a fast lane to preclinical development

The past year has been very productive at the relatively small Contract Research Organisation (CRO) Redoxis. Being specialised in preclinical drug development and efficacy evaluation models, Redoxis offers invaluable support to any pharmaceutical drug developer at the very early stages.

Nina Woodworth, COO and Malin Hultqvist, CEO at Redoxis.

“A lot of CROs tend to focus on the later phases of development, even if they still retain a preclinical approach. What we offer is support at the very first stages of development, positioning ourselves somewhere in between academic research and commercial laboratory services”, says Malin Hultqvist, CEO at Redoxis.

Redoxis has retained an academic approach to research projects and this is one of many things that differentiate the Lund-based CRO from many other, larger CROs in Scandinavia and Europe. Redoxis also remains true to the company’s initial values and vision regarding preclinical development in inflammatory, autoimmune and neurodegenerative diseases.

Completely tailored research


Redoxis provides preclinical in vivo and in vitro models, including in vivo efficacy, functional assays, mechanism of action (MoA) evaluation, ex vivo ranking, pharmacokinetic (PK) investigation, biomarker identification and biomarker analyses.

Services also include possibility for in vivo imaging in models of relevance for autoimmune diseases, in collaboration with external partners.

Malin Hultqvist sums up the company offer as a completely tailored research model for each client:

“Of course, we rely on a large portfolio of standard models but can also find solutions for specific customer requests. What makes us unique is that we are flexible and agile, even when developing entirely new research methods and models for our customers. We provide reliable results from custom-made studies that bring value to our customers’ preclinical programs”.

Meeting international needs

International companies striving to target the Scandinavian and European market often contract Redoxis to perform all stages of preclinical studies in inflammatory and autoimmune diseases. In later years Redoxis has embarked on a new path offering preclinical development services in neurodegenerative disease as well.

“There is no specific type of client for us, we strive to serve all companies and academic researchers who need support in the preclinical stages with the same dedication. Our customers can be large pharmaceutical companies or small biotech developers. They can also be part of a research team at a university”, explains Malin Hultqvist.

New resources both material and human

The past year has been productive at Redoxis. Not only in terms of new projects, but also when it comes to investing in new resources to conduct even better research projects. Resources are both material and human.

Before August this year, Redoxis will have four more experts on the team. Within two years from now, Redoxis will move into the new laboratory environment currently being built in Medicon Village in Lund.

“We have been a part of Medicon Village since the company was founded, but the move to a larger laboratory will enhance our capacity and focus even further”, says Malin Hultqvist.